<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-137853" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tafamidis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Verma</surname>
            <given-names>Bhupendra</given-names>
          </name>
          <aff>Shree Krishna Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Verma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-137853.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly. This activity will highlight the current indications, mechanism of action, dosage, contraindications, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) of tafamidis in a clinical setting pertinent for healthcare team members in the management of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) or peripheral neuropathy (ATTR-PN).</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of tafamidis.</p></list-item><list-item><p>Review the available formulations and dosage of tafamidis.</p></list-item><list-item><p>Identify the adverse events of tafamidis in clinical practice.</p></list-item><list-item><p>Outline the importance of collaboration and coordination in an interprofessional health team to improve patient outcomes when receiving tafamidis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137853">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-137853.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tafamidis is an innovative drug used to treat certain forms of ATTR amyloidosis (Transthyretin). ATTR amyloidosis is due to transthyretin (prealbumin) misfolding, which becomes unstable and deposits within the extracellular space of mainly cardiac tissue and nerves.<xref ref-type="bibr" rid="article-137853.r1">[1]</xref>&#x000a0;It is of two types: the wild or senile type (ATTRwt) and the variant type (ATTRv), also known as hereditary or familial type. ATTRwt amyloidosis presents in elderly males with a predominant cardiac phenotype: Whereas the ATTRv amyloidosis mainly presents as sensorimotor peripheral neuropathy, specifically in patients with V30M mutation.<xref ref-type="bibr" rid="article-137853.r2">[2]</xref></p>
        <p>However, in the United States, a predominantly cardiac phenotype is seen due to the high prevalence of V122I mutation (3.5%) in the African American population.<xref ref-type="bibr" rid="article-137853.r3">[3]</xref>&#x000a0;Previously, the treatment was mainly supportive in both types of ATTR amyloidosis, with the liver transplantation being reserved for the ATTRwt form.<xref ref-type="bibr" rid="article-137853.r4">[4]</xref>&#x000a0;However, the prognosis is improving with the availability of effective targeted therapies, including TTR stabilizers (tafamidis, diflunisal) and silencers (patisiran, inotersen).</p>
        <p>In the multinational ATTR-ACT study, 441 patients with cardiomyopathy (24% ATTRv and 76% ATTRwt) were randomized to receive either tafamidis 80mg or tafamidis 20mg or a placebo once daily for 30 months.<xref ref-type="bibr" rid="article-137853.r5">[5]</xref>&#x000a0;Compared to placebo, tafamidis led to significantly lower all-cause mortality (42.9% vs. 29.5%; hazard ratio= 0.70) and cardiovascular hospitalizations (0.7 per year vs. 0.48 per year; relative risk ratio= 0.68). It also reduced the decline in 6-min walk distance and health status score. In May 2019, the FDA approved tafamidis to treat ATTR cardiomyopathy (ATTR-CM) of both wild and hereditary types to reduce cardiovascular hospitalizations and mortality. Patients in NYHA class IV were not included in the study, and those with NYHA class III had increased cardiovascular hospitalizations compared to placebo. Therefore, it is prudent to start the treatment early while the patient is still in NYHA class I or II to improve long-term survival.<xref ref-type="bibr" rid="article-137853.r6">[6]</xref>&#x000a0;Cardiomyopathy associated with ATTRv has a poor prognosis compared with ATTRwt, but tafamidis showed a similar reduction in mortality and hospitalizations in both types.<xref ref-type="bibr" rid="article-137853.r7">[7]</xref></p>
        <p>In November 2011, tafamidis was approved by the European Medicines Agency (EMA) to treat ATTR amyloidosis to delay neurological progression in patients with stage 1 polyneuropathy.<xref ref-type="bibr" rid="article-137853.r8">[8]</xref> Subsequently, it has&#x000a0;received approval in more than 40 countries. In 2016, the first European consensus on transthyretin familial amyloid polyneuropathy recommended tafamidis as the standard of care in stage 1 ATTR-PN (polyneuropathy), replacing the liver transplantation.<xref ref-type="bibr" rid="article-137853.r9">[9]</xref> Early diagnosis of ATTR-PN and treatment are essential to achieve the most significant benefits.<xref ref-type="bibr" rid="article-137853.r10">[10]</xref> In the pivotal placebo-controlled Fx-005 study, including patients with early familial ATTR polyneuropathy, the disease progression in the tafamidis group did not differ significantly.<xref ref-type="bibr" rid="article-137853.r11">[11]</xref></p>
        <p>In 2019, the FDA granted tafamidis priority review, fast track, and breakthrough therapy designations to treat&#x000a0;the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). In addition, tafamidis and tafamidis meglumine also obtained orphan drug designation, which provides incentives for developing drugs for rare diseases.<xref ref-type="bibr" rid="article-137853.r12">[12]</xref>&#x000a0;The FDA has not approved tafamidis to treat ATTR polyneuropathy based on insufficient evidence of clinical efficacy.</p>
      </sec>
      <sec id="article-137853.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tafamidis is disease-modifying transthyretin (TTR) kinetic stabilizer for treating transthyretin amyloidosis (ATTR amyloidosis).<xref ref-type="bibr" rid="article-137853.r12">[12]</xref></p>
        <p>Transthyretin (TTR) is a soluble, tetrameric protein synthesized and secreted by the liver. Conformational change can occur in TTR either spontaneously with age (ATTRwt) or genetic abnormality (ATTRv), leading to destabilization and dissociation into monomers.<xref ref-type="bibr" rid="article-137853.r13">[13]</xref>&#x000a0;These monomers misfold and deposit in the extracellular space of tissues as insoluble amyloid fibrils, impairing their normal functioning. Tafamidis,&#x000a0;a selective stabilizer of TTR, selectively binds to the thyroxine-binding sites and kinetically stabilizes the TTR tetramer.<xref ref-type="bibr" rid="article-137853.r14">[14]</xref> By slowing the dissociation into monomers, the rate-limiting step of amyloid formation, tafamidis slows the disease progression in both cardiomyopathy and peripheral neuropathy.<xref ref-type="bibr" rid="article-137853.r13">[13]</xref></p>
        <p><bold>Pharmacokinetics </bold>(manufacturer's labeling)</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Absorption:</bold>&#x000a0;Peak concentration is observed within 4 hours after dosing.&#x000a0;No clinically meaningful differences in the pharmacokinetics of tafamidis are marked&#x000a0;concerning high fat/calorie food intake.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Distribution:</bold>&#x000a0;The apparent volume of distribution(Vd) of tafamidis meglumine is 16 liters and 18.5 liters for tafamidis. Tafamidis predominantly binds to TTR. Plasma protein binding of tafamidis is high(&#x0003e;99% in vitro).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metabolism:</bold>&#x000a0;Glucuronidation has been observed in clinical studies. However, the metabolism of tafamidis is not comprehensively understood.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Excretion:</bold>&#x000a0;The mean half-life of tafamidis is 49 hours, and the clearance of tafamidis meglumine is approximately 0.228 L/h and 0.263 L/h for tafamidis. Consequently, after multiple tafamidis dosing, drug accumulation is approximately 2.5-fold times greater than administration of a single dose.&#x000a0;Approximately 22% of the dose is recovered in urine (primarily as the glucuronide metabolite). Approximately 59% of the dose is recovered in feces (primarily as the unchanged drug).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-137853.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Tafamidis is administered orally and is currently available as soft capsules in the following two strengths:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tafamidis meglumine 20 mg capsules (equivalent to 12.2 mg of tafamidis free acid)</p>
          </list-item>
          <list-item>
            <p>Tafamidis free acid 61 mg capsules</p>
          </list-item>
        </list>
        <p>Dosage in ATRR cardiomyopathy (FDA-approved indication): The recommended dose is either tafamidis meglumine 80 mg (four capsules of 20 mg) or tafamidis 61 mg (single capsule) orally once daily.<xref ref-type="bibr" rid="article-137853.r13">[13]</xref>&#x000a0;Doses of 80 mg tafamidis meglumine and 61 mg tafamidis are bioequivalent, but they can not be substituted per mg.<xref ref-type="bibr" rid="article-137853.r15">[15]</xref> The capsules should be swallowed whole and can be taken with or without food. The manufacturer promotes the 61 mg capsule more because of single capsule dosing, preventing patients from self-adjusting the 20mg capsules.&#x000a0;Dosage in ATTR peripheral neuropathy (non-FDA-approved indication): The recommended dose is 20 mg of tafamidis meglumine orally once daily.<xref ref-type="bibr" rid="article-137853.r10">[10]</xref></p>
        <p><bold>Specific Patient Populations </bold>(according to manufacturer's labeling)</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatic Impairment:</bold> There are no significant differences in tafamidis in patients with mild hepatic impairment (Child-Pugh score of 5 to 6).&#x000a0;Patients with moderate hepatic impairment (Child-Pugh score 7 to 9) have decreased systemic exposure and increased clearance of tafamidis, but these patients have low TTR levels than healthy subjects. Consequently, the exposure of tafamidis relative to the amount of TTR is sufficient to maintain the stabilization of the TTR tetramer in these patients.&#x000a0;The significance of severe hepatic impairment on tafamidis is not known.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal Impairment:</bold> No clinically significant differences in the pharmacokinetics of tafamidis are observed in patients with renal impairment. But therapeutic benefit has not been&#x000a0;established with&#x000a0;impaired renal function (eGFR&#x0003c;25 mL/min/1.73 m2) based on&#x000a0;2022 AHA/ACC/HFSA guidelines.<xref ref-type="bibr" rid="article-137853.r16">[16]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy Considerations:</bold> Preclinical studies indicates that tafamidis may cause fetal harm when administered to a pregnant woman.&#x000a0;In animal reproductive studies, administration of tafamidis to pregnant rabbits resulted in adverse effects on development (embryofetal mortality and fetal malformation) at a dosage approximately nine times the human exposure (AUC) at the maximum recommended human dose (MRHD). In addition, postnatal mortality and growth retardation were observed in offspring of pregnant rats administered tafamidis meglumine approximately two times the MRHD-based on body surface area (mg/m2). Limited human data on tafamidis use in pregnant women have not identified major congenital disabilities or miscarriage, but more research is still needed. Hence, advise pregnant women of the potential risk to a fetus and consider pregnancy planning and prevention.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Breastfeeding Considerations:</bold>&#x000a0;Currently, there is no data regarding the presence of tafamidis in human milk and its effect on the breastfed infant. However, in pregnant and lactating female rats radioactivity study revealed that tafamidis meglumine is transferred to milk after oral administration. Animal studies also suggest the potential for serious adverse drug reactions in the breastfed infant. Consequently, advise patients that breastfeeding is not recommended during treatment with tafamidis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-137853.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>In the 30-month ATTR-ACT study, the frequency of adverse events was similar in the tafamidis 20 mg, tafamidis 80 mg, and the placebo groups.<xref ref-type="bibr" rid="article-137853.r5">[5]</xref>&#x000a0;However, data from long-term follow-up and clinical practice settings in ATTR-PN show the following adverse events:<xref ref-type="bibr" rid="article-137853.r10">[10]</xref><xref ref-type="bibr" rid="article-137853.r17">[17]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Headache&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Peripheral edema&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Upper abdominal pain, flatulence, diarrhea</p>
          </list-item>
          <list-item>
            <p>Influenza, pneumonia</p>
          </list-item>
          <list-item>
            <p>Acute cardiac failure</p>
          </list-item>
          <list-item>
            <p>Pain in extremity, myalgia</p>
          </list-item>
          <list-item>
            <p>Punctate keratitis</p>
          </list-item>
          <list-item>
            <p>Vaginal infection</p>
          </list-item>
          <list-item>
            <p>Laboratory abnormalities: altered neutrophil and lymphocyte count, increased liver function test and blood urea nitrogen, increased prothrombin time, reduced serum thyroxine levels</p>
          </list-item>
        </list>
        <p>Fecal incontinence and renal impairment may infrequently lead to treatment discontinuation. Severe adverse events are infrequent, with only one reported case of treatment-related pericardial effusion. One case of sudden death related to tafamidis was seen in a small Japanese study.<xref ref-type="bibr" rid="article-137853.r18">[18]</xref> However, no mortality due to tafamidis has been reported in more extensive studies.</p>
      </sec>
      <sec id="article-137853.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There is no absolute contraindication to the use of tafamidis except hypersensitivity to the active substance (tafamidis or tafamidis meglumine) or any inactive ingredients present in the capsule.&#x000a0;Tafamidis is not recommended during pregnancy or breastfeeding, and for women of childbearing potential not using contraception. Safety and effectiveness have not been established in pediatric patients.</p>
        <p>Due to sorbitol in the capsules, it should not be given to patients with hereditary fructose intolerance.&#x000a0;As mentioned in pharmacokinetics, tafamidis can be initiated in patients with mild to moderate renal and hepatic impairment; caution is recommended in severe hepatic impairment. Tafamidis should not be given in patients with liver transplants and should be discontinued after liver transplants. Tafamidis should not be given in patients with NYHA class IV symptoms, 6-minute walk distance &#x0003c;100 m, and severe renal dysfunction (estimated glomerular filtration rate &#x0003c; 25 ml per minute per 1.73 m^2) as these patients were not studied in the ATTR-ACT trial.<xref ref-type="bibr" rid="article-137853.r5">[5]</xref></p>
        <p><bold>Drug Interactions:</bold>&#x000a0;Dose adjustment may be required when used with substrates of breast cancer resistant protein (BCRP) transporter (e.g., methotrexate, rosuvastatin, imatinib). Avoid the combination of tafamidis with alpelisib, berotralstat, cladribine, ubrogepant, pazopanib, rimegepant, or topotecan.</p>
      </sec>
      <sec id="article-137853.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The success of&#x000a0;ATTR amyloidosis treatment with tafamidis is&#x000a0;monitored and assessed by echocardiograms, cardiac magnetic resonance imaging (MRI), and scintigraphy with bone tracers to diagnose infiltrative cardiomyopathy.<xref ref-type="bibr" rid="article-137853.r13">[13]</xref>&#x000a0;There are no specific recommendations but based on the available trial data; the following parameters need to be monitored periodically:<xref ref-type="bibr" rid="article-137853.r10">[10]</xref><xref ref-type="bibr" rid="article-137853.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Liver function test (LFT)</p>
          </list-item>
          <list-item>
            <p>Renal function test (RFT)</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC)</p>
          </list-item>
          <list-item>
            <p>Thyroid function test&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prothrombin time</p>
          </list-item>
          <list-item>
            <p>Biomarkers of heart failure (NT-proBNP and Troponin I)</p>
          </list-item>
          <list-item>
            <p>Electrocardiogram (EKG)-&#x000a0; Low voltage in the limb leads and/or a pseudo-infarct pattern in the precordial leads.<xref ref-type="bibr" rid="article-137853.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Changes in echocardiography measures from baseline such as left ventricular ejection fraction (LVEF), interventricular wall thickness, left ventricular stroke volume, and global longitudinal strain (as mentioned in the appendix)<xref ref-type="bibr" rid="article-137853.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Quality of life as measured by the KCCQ-OS (Kansas city cardiomyopathy questionnaire-overall summary) and six-minute walk test (6MWT)<xref ref-type="bibr" rid="article-137853.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-137853.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In clinical studies, tafamidis has been administered at a dose of 80 mg and for up to 111 months without any significant adverse events. A single dose of tafamidis of 480 mg in healthy volunteers did not show any adverse event except mild hordeolum in one patient. Two patients, during clinical trials, accidentally took 160 mg of tafamidis without any adverse event. Moreover, administering a very high dose of tafamidis in dogs (476 fold the clinical dose of 80 mg tafamidis meglumine) had no apparent adverse events. Thus, the risk of overdose in humans is extremely low. However, clinicians should give standard supportive measures in case of overdose.</p>
      </sec>
      <sec id="article-137853.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cardiomyopathy associated with ATTR amyloidosis (ATTR-CM) is debilitating and has a median survival of only 2 to 6 years.<xref ref-type="bibr" rid="article-137853.r21">[21]</xref>&#x000a0;Early diagnosis is critical because of the recent availability of targeted treatment, which is more effective when instituted early in the disease course. Due to unclear clinical benefits, tafamidis currently has FDA approval&#x000a0;only for ATTR-CM and not ATTR-PN. Delay in diagnosis and treatment mainly occurs due to fragmented knowledge among the healthcare professionals regarding clinical suspicion, availability of non-invasive diagnostic modalities, disease course and prevalence, genotypic heterogeneity, and use of targeted treatment.<xref ref-type="bibr" rid="article-137853.r22">[22]</xref></p>
        <p>An interprofessional team is critical for diagnosing, managing symptoms, optimizing nutrition, treating with tafamidis, monitoring cardiac function, and managing the adverse effects of the treatments.&#x000a0;Therefore, an integrated interprofessional healthcare team is required, including primary care physicians, cardiologists, neurologists, hematologists, pathologists, radiologists, nursing staff, and pharmacists. Due to non-specific clinical presentation, a high degree of clinical suspicion is&#x000a0;necessary from clinicians. The disease is usually suspected based on symptoms, electrocardiogram (ECG), echocardiography, cardiac biomarkers, or magnetic resonance imaging (MRI). Suspected cases of cardiac amyloidosis should undergo screening for monoclonal protein to rule out AL amyloidosis (light chain), followed by myocardial scintigraphy or cardiac biopsy as needed.<xref ref-type="bibr" rid="article-137853.r23">[23]</xref>&#x000a0;</p>
        <p>Consultation with a hematologist is&#x000a0;necessary in case of mild or doubtful elevations of serum-free light chains. The involvement of a nuclear medicine expert is essential because scintigraphy by 99mtechnetium compound is the mainstay of an early and non-invasive diagnosis of ATTR-CM. In case of any doubt, endomyocardial biopsy and evaluation by an experienced pathologist remain the gold standard of diagnosis. Genotyping is essential after diagnosis as a TTR variant requires genetic counseling from the family members. Neurological consultation may be necessary&#x000a0;if there is&#x000a0;suspicion of neurological involvement, particularly in the ATTRv type.</p>
        <p>The treating physicians and nursing staff must understand that these patients do not tolerate antihypertensive and heart failure medications. They do not offer any clinical benefit and instead can cause symptomatic hypotension. The nursing staff must give supportive treatment in consultation with the cardiologists until more definitive treatment is initiated. Tafamidis is currently the most expensive cardiovascular medication, with a yearly cost of $225,000. Therefore, clinicians must start it only after explaining the cost and expected benefit to the patient in consultation with the pharmaceutical company and the medical insurer. An integrated multidisciplinary program is required, along with a dedicated pharmacist, to ensure the availability and affordability of tafamidis.<xref ref-type="bibr" rid="article-137853.r24">[24]</xref>&#x000a0;Once&#x000a0;a clinician decides to start tafamidis, the nurse can counsel the patient on dosage and administration and monitor the clinical response in collaboration with the healthcare team. The nursing staff and pharmacist should also counsel regarding the potential harm of this drug during pregnancy, breastfeeding, and caution in women of childbearing potential. Despite an excellent safety profile of tafamidis, care&#x000a0;is necessary by the physician, nurse, and pharmacist to monitor for rare adverse events.</p>
        <p>Clinicians can advise all patients&#x000a0;on tafamidis therapy of the availability of the Transthyretin Amyloidosis Outcome Survey (THAOS) registry and their voluntary participation.<xref ref-type="bibr" rid="article-137853.r25">[25]</xref> The principal&#x000a0;aim of this THAOS survey is to understand pathophysiology, disease&#x000a0;characteristics,&#x000a0;and emerging treatment options for&#x000a0;amyloidosis by studying a&#x000a0;large and heterogeneous patient population. A long-term&#x000a0;study&#x000a0;can help develop new treatment guidelines and recommendations,&#x000a0;optimizing&#x000a0;patient care and safety.<xref ref-type="bibr" rid="article-137853.r17">[17]</xref> Thus, it must be emphasized that collaboration and coordination between the interprofessional team consisting of clinicians, specialists, nursing, and pharmacists are required to improve the outcomes of the patient.<xref ref-type="bibr" rid="article-137853.r26">[26]</xref>&#x000a0;[Level 2]</p>
      </sec>
      <sec id="article-137853.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137853&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137853">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/137853/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=137853">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-137853.s11">
        <title>References</title>
        <ref id="article-137853.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muchtar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mauermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McPhail</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Kurtin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buadi</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Dingli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Systemic amyloidosis from A (AA) to T (ATTR): a review.</article-title>
            <source>J Intern Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>289</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-292</page-range>
            <pub-id pub-id-type="pmid">32929754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.</article-title>
            <source>JAMA</source>
            <year>2020</year>
            <month>Jul</month>
            <day>07</day>
            <volume>324</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-89</page-range>
            <pub-id pub-id-type="pmid">32633805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buxbaum</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.</article-title>
            <source>Genet Med</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>733</fpage>
            <page-range>733-742</page-range>
            <pub-id pub-id-type="pmid">28102864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvalho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lobato</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Liver transplantation in transthyretin amyloidosis: issues and challenges.</article-title>
            <source>Liver Transpl</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-92</page-range>
            <pub-id pub-id-type="pmid">25482846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Waddington-Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Barsdorf</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <collab>ATTR-ACT Study Investigators</collab>
            </person-group>
            <article-title>Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>13</day>
            <volume>379</volume>
            <issue>11</issue>
            <fpage>1007</fpage>
            <page-range>1007-1016</page-range>
            <pub-id pub-id-type="pmid">30145929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garcia-Pavia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-285</page-range>
            <pub-id pub-id-type="pmid">33070419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Boman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.</article-title>
            <source>JACC Heart Fail</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-123</page-range>
            <pub-id pub-id-type="pmid">33309574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grippon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tafamidis.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2012</year>
            <month>Mar</month>
            <day>01</day>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-6</page-range>
            <pub-id pub-id-type="pmid">22378262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Hund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tournev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Slama</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hazenberg</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <collab>European Network for TTR-FAP (ATTReuNET)</collab>
            </person-group>
            <article-title>First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S14</fpage>
            <page-range>S14-26</page-range>
            <pub-id pub-id-type="pmid">26734952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Deeks</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>8</issue>
            <fpage>863</fpage>
            <page-range>863-874</page-range>
            <pub-id pub-id-type="pmid">31098895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Martins da Silva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waddington Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plant&#x000e9;-Bordeneuve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lozeron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Campistol</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Concei&#x000e7;&#x000e3;o</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Trigo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Labaudini&#x000e8;re</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Packman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Aug</month>
            <day>21</day>
            <volume>79</volume>
            <issue>8</issue>
            <fpage>785</fpage>
            <page-range>785-92</page-range>
            <pub-id pub-id-type="pmid">22843282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>See Tai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>1225</fpage>
            <page-range>1225-1243</page-range>
            <pub-id pub-id-type="pmid">33776421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nawarskas</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shephard</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.</article-title>
            <source>Cardiol Rev</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-160</page-range>
            <pub-id pub-id-type="pmid">32101907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bulawa</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Plant&#x000e9;-Bordeneuve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Labaudini&#x000e8;re</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mundayat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lombardo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Huertas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.</article-title>
            <source>Neurol Ther</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">26894299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lockwood</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>O'Gorman</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Tankisheva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 &#x000d7; 20-mg Capsules in Healthy Volunteers.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>849</fpage>
            <page-range>849-854</page-range>
            <pub-id pub-id-type="pmid">32196976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ebede</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gundapaneni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.</article-title>
            <source>Amyloid</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>203</fpage>
            <page-range>203-209</page-range>
            <pub-id pub-id-type="pmid">31353964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ando</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sekijima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Obayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Misumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Machii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.</article-title>
            <source>J Neurol Sci</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>362</volume>
            <fpage>266</fpage>
            <page-range>266-71</page-range>
            <pub-id pub-id-type="pmid">26944161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klamerus</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Watsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The effect of tafamidis on the QTc interval in healthy subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>918</fpage>
            <page-range>918-25</page-range>
            <pub-id pub-id-type="pmid">25546001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vervaat</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Bouwmeester</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vlaar</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Case report regarding the evolution of electrocardiographic and echocardiographic features in cardiac amyloidosis.</article-title>
            <source>Eur Heart J Case Rep</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>ytaa426</fpage>
            <pub-id pub-id-type="pmid">33644637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lane</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Naharro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quarta</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowczenio</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hutt</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rezk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strehina</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Caringal-Galima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharpley</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Wechalekar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachchithanantham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drage</surname>
                <given-names>EPS</given-names>
              </name>
              <name>
                <surname>Jenner</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertolli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Calleja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jul</month>
            <day>02</day>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-26</page-range>
            <pub-id pub-id-type="pmid">31109193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ambardekar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Bullock-Palmer</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <collab>American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology</collab>
            </person-group>
            <article-title>Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Jul</month>
            <day>07</day>
            <volume>142</volume>
            <issue>1</issue>
            <fpage>e7</fpage>
            <page-range>e7-e22</page-range>
            <pub-id pub-id-type="pmid">32476490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorbala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drachman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Lousada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nativi-Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cristina Quarta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Witteles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.</article-title>
            <source>Circ Heart Fail</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e006075</fpage>
            <pub-id pub-id-type="pmid">31480867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gellad</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Heitner</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History.</article-title>
            <source>JAMA Cardiol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>1066</fpage>
            <page-range>1066-1067</page-range>
            <pub-id pub-id-type="pmid">32936265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plant&#x000e9;-Bordeneuve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">23193943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137853.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Comenzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Semigran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Apr</month>
            <day>04</day>
            <volume>135</volume>
            <issue>14</issue>
            <fpage>1357</fpage>
            <page-range>1357-1377</page-range>
            <pub-id pub-id-type="pmid">28373528</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
